Samsung Bioepis And Organon Get First High-Concentration Adalimumab Nod In US
Firms Receive First FDA Approval For Higher-Strength 100mg/ml Humira Biosimilar
Executive Summary
Samsung Bioepis and Organon have broken new ground for Humira biosimilars in the US after receiving the first FDA approval for a higher-strength 100mg/ml adalimumab biosimilar.
You may also be interested in...
Celltrion Bags FDA Approval For High-Concentration Humira Rival
Celltrion USA has won US FDA approval for its Yuflyma 100mg/ml adalimumab biosimilar, making it the third high-concentration version approved in the US and the ninth Humira rival overall.
Organon Tempers Expectations Ahead Of Adalimumab Second Wave
Ahead of joining a second wave of Humira biosimilars hitting the US market in just a couple of months, Organon has projected a “modest ramp” in initial sales for its Hadlima version in 2023.
What’s Next? Five Things To Look Out For In May
Generics Bulletin previews the most notable and anticipated events for May 2023.